Expression of taste molecules in the upper gastrointestinal tract in humans with and without type 2 diabetes
- Children and Diabetes. Kaplan-Mayer, Gabrielle // Pediatrics for Parents;2004, Vol. 21 Issue 4, p4
Discusses the increase of children diagnosed with type 2 diabetes in the U.S. Definition of type 1 and type 2 diabetes; Causes of diabetes; Inclusion of the treatment.
- CHAPTER 54: DIABETES. Miller, Richard K.; Washington, Kelli D. // Healthcare Business Market Research Handbook;2006, p304
Chapter 54 of the book "The 2006 Healthcare Business Market Research Handbook" is presented. It examines the economic impact of diabetes. The complications of diabetes include nerve damage and blood vessel damage. It looks at the diabetes epidemic in the U.S. It discusses type 1 and type 2 diabetes.
- Diabetes: Is what you eat to blame? Adolphe, Nicole // Cleo;Nov2003, Issue 373, p189
Provides information on diabetes. Variations of diabetes; Factors that may cause diabetes; Diet that can help reduce the risks of Type 2 diabetes; Tips on preventing diabetes.
- Type 2 Diabetes--A Challenge for the Occupational Health Nurse. Quinn, Lauretta; Richlin, Danielle // AAOHN Journal;Feb2003, Vol. 51 Issue 2, p55
Provides information on type 2 diabetes. Prevalence of diabetes mellitus in the U.S. from 1990 to 1998; Classification of diabetes and other forms of glucose intolerance; Risk factors in the development of type 2 diabetes.
- The Burden of Treatment Failure in Type 2 Diabetes. Brown, Jonathan B.; Nichols, Gregory A.; Perry, Andrew // Diabetes Care;Jul2004, Vol. 27 Issue 7, p1535
OBJECTIVE â€” In type 2 diabetes, therapies to maintain blood glucose control usually fail after several years. We estimated the glycemic burden that accumulates from treatment failure and describe the time course and predictors of failure. RESEARCH DESIGN AND METHODS â€” A...
- Translating Lifestyle Intervention to Practice in Obese Patients With Type 2 Diabetes. Wolf, Anne M.; Conaway, Mark R.; Crowther, Jayne Q.; Hazen, Kristen Y.; Nadler, Jerry L.; Oneida, Beverly; Bovbjerg, Viktor E. // Diabetes Care;Jul2004, Vol. 27 Issue 7, p1570
OBJECTIVE â€” To assess the efficacy of a lifestyle intervention program that can be readily translated into clinical practice for obese patients with type 2 diabetes. RESEARCH DESIGN AND METHODS â€” The study consisted of a 12-month randomized controlled trial of 147 health plan...
- The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients. Charbonnel, Bernard; Dormandy, John; Erdmann, Erland; Masssi-Benedetti, Massimo; Skene, Allan; Massi-Benedetti, Massimo; PROactive Study Group // Diabetes Care;Jul2004, Vol. 27 Issue 7, p1647
Objective:The PROspective pioglitAzone Clinical Trial In macroVascular Events (PROactive) assesses the effect of pioglitazone, a peroxisome proliferator-activated receptor agonist, with anti-inflammatory and vascular properties, on the secondary prevention of macrovascular events...
- Diabetes still growing, but new treatments on the way. Levy, Sandra // Drug Topics;11/21/2005, Vol. 149 Issue 22, p16
This article examines the availability of new treatments for Types 1 and 2 diabetes, that should have a profound effect on glucose control and the complications of diabetes. Some treatments for Type 2 diabetes can target the following underlying causes of diabetes: decreased insulin secretion,...
- Type 2 diabetes mellitus: a high-risk condition for cardiovascular disease irrespective of the different degrees of obesity. S.H. Song; C.A. Hardisty // QJM: An International Journal of Medicine;Nov2008, Vol. 101 Issue 11, p875
Background: Measurement of body weight with body mass index (BMI) is often utilized to stratify cardiovascular disease (CVD) risk. Aim: To determine CVD risk profile and disease burden in subjects with type 2 diabetes mellitus (T2DM) across different categories of body weight as defined by BMI....
- Elevated Plasma Glucose-Dependent Insulinotropic Polypeptide Associates With Hyperinsulinemia in Impaired Glucose Tolerance. Theodorakis, Michael J.; Carlson, Olga; Muller, Denis C.; Egan, Josephine M. // Diabetes Care;Jul2004, Vol. 27 Issue 7, p1692
OBJECTIVE â€” The role of gut-derived incretin, glucose-dependent insulinotropic polypeptide (also known as gastric inhibitory peptide [GIP]), in compensatory Î²-cell hypersecretion during insulin-resistant states and in transition to Î²-cell failure in type 2 diabetes is unknown....